Anwaar Saeed - Publications, H-index & Citations

Anwaar Saeed

upmc

33H指数

406论文数

4.2K被引数

收录论文 85

发表时间

The double-edged sword of PD‑1/PD‑L1 blockade: Bridging hepatocellular carcinoma to liver transplantation while minimizing allograft injury PD‑1/PD‑L1阻断的双刃剑：连接肝细胞癌与肝移植同时最小化移植物损伤

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2026-09-08

PREAI

Pooya Jalali; Andy Wu; Shahd Alkhazna; Stela Celaj; Anwaar Saeed

FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer FOLFOXIRI联合帕尼单抗治疗左侧RAS野生型转移性结直肠癌

Oncologist

IF4.2

2026-08-18

OAAI

Howard S Hochster; Patrick J Blatchford; Stacey Stein; Jill Lacy; Anup Kasi; Patrick M Boland; Philp Gold; Aaron J Scott; Paul Oberstein; Michael Cusnir; Kate Rouse; Karen Mallalieu; Anwaar Saeed; For the AGICC Group; null

Host-Microbiome Integration as a Biomarker Framework in Esophageal Cancer: Current Evidence and Translational Challenges 宿主-微生物组整合作为食管癌生物标志物框架：当前证据与转化挑战

Current Issues in Molecular Biology

IF3

2026-08-16

OAAI

Shamimeh Pourbahrighesmat; Alireza Tojjari; George Laliotis; Anwaar Saeed

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease EMPIRE (NSABP FC-13)：一项基于生物标志物的II期平台试验，评估微卫星稳定型结直肠癌中基于ctDNA定义的微小残留病灶的西米普利单抗免疫疗法

Future Oncology

IF2.6

2026-06-25

PREAI

Anwaar Saeed; Greg Yothers; Shannon L. Puhalla; Alireza Tojjari; Priya Rastogi; Tanner J. Freeman; Melissa Divya Mathias; Frank A. Seebach; Norman Wolmark; Thomas J. George

ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma ASO可视化摘要：血浆外泌体中KRAS突变等位基因频率动态变化：与局限性胰腺腺癌预后的关联

Annals of Surgical Oncology

IF3.5

2025-12-12

PREAI

Asmita Chopra; Hong-Zhang He; Jadranka Milosevic; Nikhil Tirukkovalur; Rudy El Asmar; Ibrahim Nassour; Geoffrey Nunns; Mingxi Chen; Jiaqi Chen; Siyu Jiang; Aatur D. Singhi; Anwaar Saeed; Janie Zhang; Kenneth Lee; Amer Zureikat; Si-Yang Zheng; Alessandro Paniccia

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer NCI 10211：一项伯佐塞蒂布与伊立替康联合治疗TP53突变型晚期胃肠癌的II期单臂研究

ONCOLOGIST

IF4.2

2025-12-01

OAAI

Wheless, Margaret C.; Stockton, Shannon; Soares, Heloisa P.; Dayyani, Farshid; Saeed, Anwaar; Kim, Edward; Jin, Ning; Yacoub, George; Florou, Vaia; Ayers, Gregory D.; Guerrouahen, Bella S.; Contreras, Alejandro; Li, Li; Ferry-Galow, Katherine, V; Gore, Steven; Das, Satya; Berlin, Jordan

Trends and projected burden of early-onset gastrointestinal malignancies in the United States: a population-based analysis (2001-2021)2001-2021年美国早发性胃肠道恶性肿瘤的趋势及预估负担：一项基于人群的分析

JNCI-Journal of the National Cancer Institute

IF7.2

2025-12-01

PREAI

Yasinzai, Abdul Qahar K.; Jalali, Pooya; Syaj, Sebawe; Sahin, Ibrahim Halil; Nassour, Ibrahim; George, Thomas J.; Saeed, Anwaar

Efficacy and Safety of Intraperitoneal Paclitaxel-Based Regimens in Patients with Gastric Cancer and Peritoneal Metastasis: A Systematic Review and Meta-Analysis 腹腔内紫杉醇为基础方案在胃癌伴腹膜转移患者中的疗效与安全性：一项系统评价和Meta分析

European Journal of Surgical Oncology

IF2.9

2025-11-21

PREAI

Muhammad Bakhtiar; Sepideh Razi; Rabeea Ahmed; Mahnoor Mahnoor; Ahmad Ismail; Samer AlMasri; Geoffrey Nunns; Alessandro Paniccia; Melanie C. Ongchin; Amer Zureikat; James Pingpank; Haroon Choudry; Anwaar Saeed

Trastuzumab Deruxtecan: Redefining Precision Oncology Across HER2-Driven Cancers 曲妥珠单抗德鲁替康：重新定义HER2驱动癌症中的精准肿瘤学

Critical Reviews in Oncology/Hematology

IF0

2025-11-20

PREAI

Pooya Jalali; Azhar Saeed; Sahar Taher; Anwaar Saeed

CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation CAR-T细胞疗法在肝细胞癌中的应用：从机制洞见到临床转化

Cancer Treatment Reviews

IF10.5

2025-11-10

OAAI

Reza Elahi; Yassine Alami Idrissi; Anwaar Saeed

KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma 血浆外泌体中KRAS突变等位基因频率动力学：与局限性胰腺腺癌预后的关联

Annals of Surgical Oncology

IF3.5

2025-11-04

PREAI

Thermal ablation versus surgical resection for colorectal liver metastases: a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-assessed systematic review, survival meta-analysis, and meta-regression 热消融与手术治疗结直肠癌肝转移的比较：一项经GRADE评估的系统评价、生存Meta分析和Meta回归研究

Translational Cancer Research

IF1.7

2025-11-01

PREAI

Ansab, Muhammad; Razi, Sepideh; Rath, Shree; Alam, Umama; Ramzan, Noor Ul Huda; Burhan, Muhammad; Iqbal, Asad; Saeed, Anwaar

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial Zanzalintinib联合atezolizumab与regorafenib对比治疗难治性结直肠癌(STELLAR-303)：一项随机、开放标签、III期临床试验

The Lancet

IF97.3

2025-10-20

PREAI

J Randolph Hecht; Young Suk Park; Josep Tabernero; Myung-Ah Lee; Soohyeon Lee; Anna C Virgili; Marc Van den Eynde; Elisa Fontana; Marwan Fakih; Gholamreza Asghari; Jane So; Alexander Stein; Olivier Dubreuil; Lubomir Bodnar; Cixin Steven He; Guan Wang; Robina Smith; Cathy Eng; Anwaar Saeed

Chemoimmunotherapy in Advanced Biliary Tract Cancers: A Meta-Analysis of Clinical Outcomes 晚期胆道癌的化疗免疫疗法：临床结局的荟萃分析

Biomedicines 2025, Vol. 13, Page 2099

IF3.9

2025-08-29

OAAI

Alireza Tojjari; Sepideh Razi; Osama M. Younis; Ramez M. Odat; Ibrahim Halil Sahin; Anwaar Saeed

Corrigendum to “Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis” [Cancer Treat. Rev. 133 (2025) 102882]勘误：“Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis” [Cancer Treat. Rev. 133 (2025) 102882]

Cancer Treatment Reviews

IF10.5

2025-07-15

OAAI

Isabella Michelon; Caio E.R. Castro; Thiago Madeira; Maria Inez Dacoregio; Carlos Stecca; Leonardo R. Soares; Anwaar Saeed; Maysa Vilbert; Ludimila Cavalcante

Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis Cheng, S.; Gomez, C.G.; Ferrell, M.; Giza, R.; Syed, M.P.; Magge, T.; Gorantla, V.; Hsieh, R.W.; Bao, R.; Singhi, A.; 等. 研究HER2扩增的结直肠癌中RAS/RAF和PIK3CA变异的发生率：一项综合分析。Oncologist 2025, 30, oyaf158. [Google Scholar] [CrossRef]

ONCOLOGIST

IF4.2

2025-07-01

OAAI

Cheng, Svea; Gomez, Cyndi Gonzales; Ferrell, Morgan; Giza, Richard; Syed, Masood Pasha; Magge, Tara; Gorantla, Vikram; Hsieh, Ronan W.; Bao, Riyue; Singhi, Aatur; Saeed, Anwaar; Sahin, Ibrahim Halil

Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer II期研究评估elraglusib（9-ING-41），一种GSK-3β抑制剂，与吉西他滨联合nab-紫杉醇用于既往未治疗的转移性胰腺癌。

ESMO Open

IF8.3

2025-06-01

OAAI

D. Mahalingam; A. Saeed; S.F. Powell; M. Huerta; V. Sahai; A.L. Coveler; E.J. Davis; N. Steeghs; M. Mulcahy; A.G. Raufi; L. Cavalcante; A. Cervantes; J. Berlin; T. Weisskittel; A. Ugolkov; A.P. Mazar; W. Mikrut; S. Smith; F.J. Giles; B.A. Carneiro

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy 在免疫治疗时代，揭示肛门鳞状细胞癌中PD-L1在免疫细胞预测性生物标志物和可操作遗传变异中的作用

ESMO Open

IF8.3

2025-06-01

OAAI

G. Sharma; Y. Baca; A.F. Shields; A. Prakash; B.A. Weinberg; A. Saeed; S. Goel; A. Abdalla; M. Oberley; J. Xiu; J. Hwang; E.S. Antonarakis; V.K. Chiu; E. Lou

S2303: phase II/III trial of paclitaxel plus ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)S2303: 紫杉醇联合雷莫芦单抗 ± nivolumab治疗胃和食管腺癌 (PARAMUNE) 的II/III期试验

FUTURE ONCOLOGY

IF2.6

2025-03-01

OAAI

Saeed, Anwaar; Colby, Sarah; Oberstein, Paul Eliezer; Duda, Dan G.; Park, Robin; Agarwal, Rajiv; Figueroa-Moseley, Colmar; Vaidya, Riha; Unger, Joseph M.; Guthrie, Katherine A.; Rocha, Flavio G.; Senthil, Maheswari; Safyan, Rachael A.; Wainberg, Zev A.; Iqbal, Syma; Chiorean, E. Gabriela; Philip, Philip A.

Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients 老年非小细胞肺癌患者（≥80岁）的肿瘤免疫表型相关性及PD-L1高表达（≥50%）患者接受一线帕博利珠单抗治疗的结局

Clinical Lung Cancer

IF3.3

2025-02-04

PREAI

Adriana P.C. Barrichello; Arielle Elkrief; Biagio Ricciuti; Teja Ganta; Thomas U. Marron; Xinan Wang; William Lotter; James Lindsay; Valentina Santo; Alessio Cortellini; Bijaya Sharma; Kristen Felt; Kathleen Pfaff; Giuseppe Lamberti; Federica Pecci; Alessandro Di Federico; Maisam Makarem; Malini M. Gandhi; Tom Nguyen; Danielle Haradon; Victor R. Vaz; Bruce E. Johnson; Neha Debnath; Yinghong Wang; Andrew G. Kuang; Anwaar Saeed; Maluki Radford; Christine M. Lovly; Caroline A. Nebhan; David J. Pinato; Scott J. Rodig; Adam J. Schoenfeld; Mark M. Awad; Joao V. Alessi; Abdul Rafeh Naqash

研究方向